

# 2020 Annual General Meeting

Professor Jonathan West, Chairman

17<sup>th</sup> November 2020

# Questions and Voting

---



Ask a Question



Ask a Question

Get Voting Card



Get a voting card

# Voting Card



ABC COMPANY PTY LTD X123456789

## Voting Card

Please complete your vote by selecting the required voting instruction (For, Against or Abstain) for each resolution. If you would like complete a partial vote, please specify the number of votes for each resolution in the Partial Vote section. Proxy holder votes will only be applied to discretionary (undirected) votes. Directed votes will be applied as per the the Unitholder's voting instructions.

Full Vote  Partial Vote

<b>Resolution 2B</b>	<input checked="" type="radio"/> For	<input type="radio"/> Against	<input type="radio"/> Abstain
RE-ELECTION OF MR. ABC AS A DIRECTOR			
<b>Resolution 2C</b>	<input checked="" type="radio"/> For	<input type="radio"/> Against	<input type="radio"/> Abstain
RE-ELECTION OF MS XYZ AS A DIRECTOR			
<b>Resolution 3</b>	<input checked="" type="radio"/> For	<input type="radio"/> Against	<input type="radio"/> Abstain
INCREASE TO DIRECTORS' MAXIMUM FEE POOL LIMIT			
<b>Resolution 4</b>	<input checked="" type="radio"/> For	<input type="radio"/> Against	<input type="radio"/> Abstain
ADOPTION OF REMUNERATION REPORT			

**SUBMIT VOTE**

## Sample Voting Card

Place your vote by clicking on the 'For', 'Against', or 'Abstain' voting buttons.

# 2020 Annual General Meeting

Professor Jonathan West, Chairman

17<sup>th</sup> November 2020

# 2020 Annual General Meeting

Michael Aldridge, Managing Director & CEO

17 November 2020



# Introduction

- **Hexima is an Australian biotechnology company developing HXP124, a potential new topical treatment for onychomycosis**
- **Onychomycosis (fungal nail infection) represents a large and growing market with substantial unmet need**
  - Estimated to affect up to 14% of the population, **globally the market for treatment of onychomycosis has been estimated at US\$3.7 bn.**
  - Well developed market in US and Japan with sales of the leading topical product, efinaconazole, exceeding US\$320m in 2019
  - Current topical products suffer from poor efficacy rates and long treatment durations, oral treatments are more effective but can have toxic side effects
- **HXP124 is a potentially game-changing treatment**
  - Demonstrated in a phase I/IIa clinical trial to have a favourable safety profile and deliver effective and rapid anti-fungal treatment
    - **High efficacy** via a topical application with novel mode of action
    - **Fast acting treatment** reducing treatment duration
    - **No toxic side effects**
  - Currently in an Australian phase IIb clinical trial for onychomycosis
- **HXP124 represents a compelling commercial opportunity in the US and globally**
  - Hexima aims to position HXP124 to be the **treatment of choice for an unsatisfied, consumer-driven market**
- **Hexima’s highly experienced management and scientific team and commercial board of directors have a strong track record in bringing novel biotech solutions to market**

## Significant progress in 2020

Technology (HXP124)	Leadership	Capital Funding
<ul style="list-style-type: none"><li>• Completed phase I/IIa</li><li>• Initiated phase IIb</li><li>• Established large scale manufacturing</li></ul>	<ul style="list-style-type: none"><li>• Changes to make-up of Board</li><li>• New executive management</li></ul>	<ul style="list-style-type: none"><li>• A\$5.5 million private placement</li><li>• A\$3.0 million public offering</li><li>• ASX listing</li></ul>



---

# Technology (HXP124)

Significant progress in 2020

# Phase I/IIa clinical trial

## HXP124 delivered effective and rapid anti-fungal treatment



### Key Insights from Phase I/IIa clinical trial




**Mycological cure** (culture and stain negative) was achieved in **52% of HXP124-treated nails** within 12 weeks (vehicle 24%)



HXP124 produced a high **Mycological Cure\*** rate at 12 weeks, ~2-fold higher than current treatments, after only 6 weeks of treatment

Mycological Cure at 12 weeks




Note: \*Mycological Cure = no fungus in samples collected from underneath the nail as assessed by stain (microscopy) and culture (growth).





# Phase I/IIa clinical trial

## HXP124 substantially improved onychomycosis symptoms




HXP124 cleared the affected nail area more effectively than formulation not containing HXP124



Clinical efficacy (defined as <10% of the nail area affected) was **achieved in 20% of HXP124-treated nails** within just 12 weeks (vehicle 6%)

Clinical efficacy (<10% infected nail area) over time






# Australian Phase IIb clinical trial

- Multi-center, randomised, double blind, vehicle-controlled study
- Three active arms versus vehicle (132 subjects)
  - Comparing three dosing strategies
- Safety & efficacy assessed at 13, 24, 36 and 40 weeks
- First patient dosed October 2020, expect results Q1 2022

## 36-week treatment – 40-week follow-up





---




# Leadership

Important changes to make-up of Leadership



# Changes to make-up of Board and Executive Management

## Board of Directors and Senior Executive Team



**Prof. Jonathan West**  
Non-Executive Chair

- Former Assoc. Prof. at Harvard Business School
- Founding Director of Australian Innovation Research Centre
- Advisor to major corporates including DuPont, Roche, Novartis and Syngenta.

3.3%  
ownership

**Mr Justin Yap**  
Non-Executive Director

- Executive Director of CathRx Limited
- Co-founder of Wilhelm Integrated Solutions
- Formerly at Mosaic Risk Management (Wilson HTM)

10.5%  
ownership

**Scott Robertson**  
Non-Executive Director

- MBA (Haas School of Business)
- Former Business Development Director at DuPont Pioneer
- Former investment professional at MPM Capital, a life science-dedicated venture capital fund
- Current CFO at DiCE Molecules

0.2%  
ownership

**Michael Aldridge**  
Managing Director &  
Chief Executive Officer

- CEO Peplin Inc., sold to Leo Pharma in 2009 for \$300M
- SVP Corporate Strategy Questcor, sold to Mallinckrodt in 2014 for US\$5.6b
- SVP Corporate & Strategic Development Codexis, US\$357M partnership with Nestle in PKU in 2017

1.8%  
ownership

**Dr. Nicole van der Weerden**  
Executive Director  
Chief Operating Officer

- PhD (La Trobe University)
- MBA (Melbourne Business School)
- Inventor on all of Hexima's key patents
- Led discovery and development program for HXP124
- CEO of Hexima 2015 -2020

1.3%  
ownership

**Prof. Marilyn Anderson AO**  
Executive Director  
Chief Science Officer

- Founding scientist of Hexima
- Fellow of the Australian Academy of Science and Australian Academy of Technological Sciences
- Executive Director of Hexima since 2010

1.7%  
ownership

**Dr Peter Welburn**  
Chief Development Officer

- CSO and VP Research & Development Peplin Inc., NDA for PEP005 Gel approved 2012
- General Manager Leo Pharma (Australia)
- Consultant to Codexis on CDX6114 for PKU

0.4%  
ownership



---

# Capital Funding

Secured Funding for Critical Next Steps



## 2020: Placement and public offer (with ASX listing)

USE OF FUNDS AND EXISTING CASH	A\$M
Existing Cash Balances as at 30 September 2020	\$5.5
R&D tax incentive refund (expected November 2020)	1.9
Gross Proceeds of the Offer	3.0
<b>Total Cash on Completion of the Public Offer</b>	<b>10.4</b>
Phase IIb clinical trial	3.4
Scale-up of HXP124 manufacture	1.2
Formulation, stability & chemistry, manufacture & controls	0.7
Toxicology studies	2.0
Market research	0.1
Costs of the Offer	0.7
Working capital	2.4
<b>TOTAL</b>	<b>\$10.4</b>

INDICATIVE TIMETABLE	2020
Prospectus Lodgement	15 October
Offer opens	22 October
Share Sale Facility closes	4 November
Public Offer closes	13 November
Shares commence trading on ASX	Expected 1 December


Indicative timetable is subject to change

Funding to deliver Phase IIb trial & IND



# HXP124 product development roadmap, key milestones

## Product development activities and timeline



Note: \* IND = Investigational New Drug Application, required to conduct clinical trials in the US; \*\* FDA = US Food and Drug Administration;



# Significant Progress in 2020

---

- **Technology (HXP124)**

- Powerful evidence of activity from Phase I/IIa clinical trial
- Planned and implemented Phase IIb clinical trial
- Mapped out pathway into Phase III clinical trials

- **Leadership**

- Recent appointments bring the skills and expertise to advance the successful development of HXP124 to market

- **Capital Funding**

- Post current public offering sufficient capital to deliver on the critical phase IIb clinical trials

**Hexima believes HXP124 represents a compelling commercial opportunity in the US and globally**



# 2020 Annual General Meeting

Michael Aldridge, Managing Director & CEO

17<sup>th</sup> November 2020

# 2020 Annual General Meeting

Professor Jonathan West, Chairman

17<sup>th</sup> November 2020

# Financial Statements and Reports

---



To receive and consider the Financial Report, Directors' Report and Auditor's Report of the Company for the year ended 30 June 2020.

# Resolution 1: Remuneration Report

---



RESOLUTION 1 - “That the Remuneration Report of the Company for the year ended 30 June 2020 be adopted and approved.”

# Resolution 1: Remuneration Report

---



Details of Proxies for Resolution 1 – representing 7,132,451 valid voting shares are:

For	51.702 %
Open	47.279 %
Against	01.019 %

# Resolution 2: Re-election of Professor Jonathan West

---



RESOLUTION 2: “That Professor Jonathan West retires in accordance with the Company's Constitution and being eligible, offers himself for re-election, be re-elected as a Director of the Company.”

# Resolution 2: Re-election of Professor Jonathan West

---



Details of Proxies for Resolution 2 – representing 16,832,646 valid voting shares are:

For	79.805 %
Open	20.090 %
Against	00.105 %

# Resolution 3: Approval of the Company's Long Term Incentive Plan

---



RESOLUTION 3: “That the Long-Term Incentive Plan for employees, directors and consultants of the Company and each Group Member, a summary of the terms of which are described in the Explanatory Statement, be approved and adopted by the Company.”



# Resolution 3: Approval of the Company's Long Term Incentive Plan

---



Details of Proxies for Resolution 3 – representing 13,504,673 valid voting shares are:

For	74.440 %
Open	24.970 %
Against	00.590 %

# Resolution 4: Approval of the U.S. Sub-Plan

---



RESOLUTION 4: “That the U.S. Sub-Plan for employees, directors and consultants of the Company and each Group Member who are U.S. residents or subject to U.S. federal income tax, a summary of the terms of which are described in the Explanatory Statement, be approved and adopted by the Company.”

# Resolution 4: Approval of the U.S. Sub-Plan

---



Details of Proxies for Resolution 4 – representing 16,826,146 valid voting shares are:

For	79.639 %
Open	20.041 %
Against	00.320 %

# 2020 Annual General Meeting Questions?

17<sup>th</sup> November 2020

# 2020 Annual General Meeting

17<sup>th</sup> November 2020